Skip to main content
Springer Nature Link
Log in

Psychopharmacology of borderline personality disorder

  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

Psychopharmacology is widely used in the treatment of borderline personality disorder. However, support for this form of treatment has been largely based on case reports, case series, and open-label clinical trials. This evidence-based review examines the most recent randomized controlled trials of psychopharmacology in the treatment of borderline personality disorder, with a goal of highlighting the most promising pharmacotherapy for use in current clinical practice, as well as for future large-scale research testing. The results and limitations of the randomized controlled trial data are presented along with case vignettes illustrating the complexity of the disorder and the heterogeneity of its treatment. To date, there is at least some evidence-based support for the use of antipsychotics (conventional and atypical), monoamine oxidase inhibitors, serotonin reuptake inhibitors, and omega-3 fatty acids in the treatment of borderline personality disorder.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Gunderson JG, Kolb JE: Discriminating features of borderline patients. Am J Psychiatry 1978, 135:792–796.

    PubMed  CAS  Google Scholar 

  2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders,edn 4-TR. Washington, DC: American Psychiatric Press, Inc; 2000.

    Book  Google Scholar 

  3. Swartz M, Blazer D, George L, Winfield I: Estimating the prevalence of borderline personality disorder in the community. J Personal Disord 1990, 4:257–272.

    Google Scholar 

  4. Clarkin JF, Widiger TA, Frances A, et al.: Prototypic typology and the borderline personality disorder. J Abnorm Psychol 1983, 92:263–275.

    Article  PubMed  CAS  Google Scholar 

  5. McGlashan TH: The Chestnut Lodge follow-up study, III: long-term outcome of borderline personalities. Arch Gen Psychiatry 1986, 43:20–30.

    PubMed  CAS  Google Scholar 

  6. Comtois KA, Russo J, Snowden M, et al.: Factors associated with high use of public mental health services by persons with borderline personality disorder. Psychiatr Serv 2003, 54:1149–1154.

    Article  PubMed  Google Scholar 

  7. Hengeveld MW, Rooymans HG, Vecht-van den Bergh R: Psychiatric consultation in a Dutch university hospital: a report on 1814 referrals, compared with a literature review. Gen Hosp Psychiatry 1984, 6:271–279.

    Article  PubMed  CAS  Google Scholar 

  8. Lahmeyer HW, Reynolds CF, III, Kupfer DJ, King R: Biological markers in borderline personality disorder: a review. J Clin Psychiatry 1989, 50:217–225.

    PubMed  CAS  Google Scholar 

  9. Levitt AJ, Joffe AT, Ennis J, et al.: The prevalence of cyclothymia in borderline personality disorder. J Clin Psychiatry 1990, 51:335–339.

    PubMed  CAS  Google Scholar 

  10. Deltito J, Maritn L, Riefkohl J, et al.: Do patients with borderline personality disorder belong to the bipolar spectrum? J Affect Disord 2001, 67:221–228.

    Article  PubMed  CAS  Google Scholar 

  11. Linehan MM, Kanter JW, Comtois KA: Dialectical behavior therapy for borderline personality disorder: efficacy, specificity, and cost-effectiveness. In Psychotherapy: Indications and Outcomes. Washington, DC: American Psychiatric Press; 1999.

    Google Scholar 

  12. Verheul R, Van Den Bosch LM, Koeter MW, et al.: Dialectical behavior therapy for women with borderline personality disorder: 12-month, randomized clinical trial in The Netherlands. Br J Psychiatry 2003, 182:135–140.

    Article  PubMed  Google Scholar 

  13. Rizvi SL, Linehan MM: Dialectical behavior therapy for personality disorders. Curr Psychiatry Rep 2001, 3:64–69.

    PubMed  CAS  Google Scholar 

  14. Gunderson JG: Borderline Personality Disorder: A Clinical Guide. Washington, DC: American Psychiatric Press; 2001.

    Google Scholar 

  15. DeBattista C, Mueller K: Is electroconvulsive therapy effective for the depressed patient with comorbid borderline personality disorder? J ECT 2001, 17:91–98.

    Article  PubMed  CAS  Google Scholar 

  16. Practice guideline for the treatment of patients with borderline personality disorder. http://www.psych.org/ psych_pract/treatg/pg/borderline_revisebook_index.cfm. Accessed Feb 12, 2004.

  17. Sanderson C, Swenson C, Bohus M: A critique of the American Psychiatric Practice Guideline for the Treatment of Patients with Borderline Personality Disorder. J Personal Disord 2002, 162:122–129.

    Article  Google Scholar 

  18. Goldberg SC, Schulz SC, Schulz PM, et al.: Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Arch Gen Psychiatry 1986, 43:680–686.

    PubMed  CAS  Google Scholar 

  19. Soloff PH, George A, Nathan RS, et al.: Progress in pharmacotherapy of borderline disorders: a double-blind study of amitriptyline, haloperidol, and placebo. Arch Gen Psychiatry 1986, 43:691–697. This landmark RCT was the first to show efficacy of haloperidol in the treatment of borderline patients. At the same time, it showed lack of efficacy of amitriptyline, putting a moratorium on further RCT research of tricyclic antidepressants in BPD. The efficacy of haloperidol demonstrated in this trial was not replicated in the authors’ subsequent trial [31].

    PubMed  CAS  Google Scholar 

  20. Cowdry RW, Gardner DL: Pharmacotherapy of borderline personality disorder. Arch Gen Psychiatry 1988, 45:111–119.

    PubMed  CAS  Google Scholar 

  21. Frankenburg FR, Zanarini MC: Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry 2002, 63:442–446.

    PubMed  CAS  Google Scholar 

  22. De la Fuente JM: A trial of carbamazepine in borderline personality disorder. Eur Neuropsychopharmacol 1994, 4:479–486.

    Article  PubMed  Google Scholar 

  23. Zanarini MC, Frankenburg FR: Omega-3 fatty acid treatment of women with borderline personality disorder: a doubleblind, placebo-controlled pilot study. Am J Psychiatry 2003, 160:167–169. This is the most recent RCT in the treatment of BPD. It demonstrates efficacy of omega-3 fatty acids, which are a trendy therapy thought to have anti-inflammatory properties; many disciplines in medicine are studying the effects of this naturally occurring compound in a wide variety of disease processes.

    Article  PubMed  Google Scholar 

  24. Mickleborough TD, Murray RL, Ionescu AA, Lindley MR: Fish oil supplementation reduces severity of exercise-induced bronchoconstriction in elite athletes. Am J Respir Crit Care Med 2003, 168:1181–1189.

    Article  PubMed  Google Scholar 

  25. Thies F, Garry JM, Yaqoob P, et al.: Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomized controlled trial. Lancet 2003, 361:477–485.

    Article  PubMed  CAS  Google Scholar 

  26. Zanarini MC, Frankenburg FR: Olanzapine treatment of female borderline personality disorder patients: a doubleblind, placebo-controlled pilot study. J Clin Psychiatry 2001, 62:849–854. This is the first pilot RCT to show efficacy of a low-dose atypical antipsychotic. This medication class is now a mainstay in the symptomatic control of BPD, particularly in patients with cognitiveperceptual distortions.

    Article  PubMed  CAS  Google Scholar 

  27. Frankenburg FR, Zanarini MC: Clozapine treatment of borderline patients: a preliminary study. Compr Psychiatry 1993, 34:402–405.

    Article  PubMed  CAS  Google Scholar 

  28. Salzman C, Wolfson AN, Schatzberg A, et al.: Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacology 1995, 15:23–29. This is the first RCT to show the efficacy of an SSRI, now the most widely prescribed class of psychotropic medication in the treatment of BPD.

    Article  CAS  Google Scholar 

  29. Rinne T, van den Brink W, Wouters L, van Dyck R: SSRI treatment of borderline personality disorder: a randomized, placebocontrolled clinical trial for female patients with borderline personality disorder. Am J Psychiatry 2002, 159:2048–2054. This RCT is the most recent SSRI trial that uses a larger sample size (albeit in a women-only population) to make positive efficacy claims in the treatment of BPD.

    Article  PubMed  Google Scholar 

  30. Hollander E, Allen A, Lopez RP, et al.: A preliminary doubleblind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry 2001, 62:199–203.

    Article  PubMed  CAS  Google Scholar 

  31. Soloff PH, Cornelius J, Anselm G, et al.: Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry 1993, 50:377–385. This is the largest RCT in BPD to date. It is arguably the most elegant because of the continuation study phase [32]. Although this study seems to refute the efficacy of haloperidol in BPD, it is important in confirming the efficacy of monoamine oxidase inhibitors at least during the early treatment phase of BPD.

    PubMed  CAS  Google Scholar 

  32. Cornelius JR, Soloff PH, Perel JM, Ulrich RF: Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine. Am J Psychiatry 1993, 150:1843–1848.

    PubMed  CAS  Google Scholar 

  33. Zanarini MC, Frankenburg FR, Khera GS, Bleichmar J: Treatment histories of borderline inpatients. Compr Psychiatry 2001, 42:144–150.

    Article  PubMed  CAS  Google Scholar 

  34. The McLean Center for the Treatment of Borderline Personality Disorder. http://www.mcleanhospital.org/Adult/borderline.html. Accessed February 12, 2004.

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine and Psychiatry, Duke University Medical Center, PO Box 3369 DUMC, 27710, Durham, NC, USA

    Y. Pritham Raj MD

Authors
  1. Y. Pritham Raj MD
    View author publications

    You can also search for this author inPubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Raj, Y.P. Psychopharmacology of borderline personality disorder. Curr Psychiatry Rep 6, 225–231 (2004). https://doi.org/10.1007/s11920-004-0068-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11920-004-0068-y

Keywords